On Aug. 9, 2023, reMind hosted a webinar with three psychedelic industry experts to discuss strategies and best practices of launching and operating a successful ketamine clinic, including establishing a mission, business plan, client care protocols, fundraising strategies, brand awareness, and location design. The panelists included: Kim Turpin, co-founder of the Pearl Psychedelic Institute; Nykol […]
Katherine MacLean is an accomplished research scientist who has studied the effects of psychedelics on cognitive performance, emotion wellbeing, spirituality, and brain function. As a post doctoral research fellow and faculty member at Johns Hopkins, she worked with Roland Griffiths on the groundbreaking clinical trials of psilocybin that were featured in Michael Pollan’s “How to […]
Derrick Knudsen is a founding partner of Meta Talent Group, a job-placement agency focused on the cannabis and psychedelics industries and strives to be “a bridge for growing companies and purpose-driven leaders who are seeking to improve the world socially and environmentally.” Earlier this year, Knudsen’s firm published its 2023 Psychedelic Salary Guide, which analyzes […]
Dr. Raymond Turpin is the clinical director for The Pearl Psychedelic Institute in Waynesville, North Carolina, and co-principal investigator of The Pearl MDMA Project. He has been studying the therapeutic uses of psychedelics and the relevant literature since the mid-1980s hoping to eventually legally use these medicines in his psychology practice. Dr. Turpin recently shared some […]
Tori Armbrust is founder of Satori Farms PDX, the first company to receive a license to manufacture psilocybin mushrooms in Oregon. A long-time mushroom enthusiast, cultivator, and educator, she is currently working with many of the new service centers opening under the rollout of Measure 109 by the Oregon Psilocybin Services Section. Armbrust recently shared […]